Dopamine agonists in parkinson's disease

Erik Ch. Wolters; Gerrit Tissingh; Paul L.M. Bergmans; Michael A. Kuiper; Y. Agid; P. Cervera; E. Hirsch; O. Hornykiewicz; S. J. Kish; G. E. Alexander; M. D. Crutcher; H. Bergman; T. Wichmann; M. R. Delong; G. E. Alexander; M. R. Delong; P. L. Strick; H. J. Groenewegen; H. W. Berendse; J. G. Wolters; C. R. Gerfen; J. F. McGinty; W. S. Young; A. R. Crossman; B. Fornstedt; E. Pileblad; A. Carlsson; N. Ogawa; R. Edamatsu; K. Mizukawa; C. C. Chiueh; H. Miyake; M. T. Peng; S. B. Blunt; P. Jenner; C. D. Marsden; P. Jenner; D. T. Dexter; J. Sian; C. W. Olanow; I. J. Kopin; P. H. Andersen; J. A. Gingrich; M. D. Bates; R. W. Fuller; J. A. Clemens; D. L. Felten; S. Y. Felten; R. W. Fuller; J. L. Waddington; K. M. O'boyle; J. K.C. Tsui; R. F. Wolters; B. Gomez-Mancilla; R. Boucher; C. Gagnon; M. Emre; U. K. Rinne; A. Rascol; R. J. Vermeulen; B. Drukarch; M. C.R. Sahadat; J. C. Stoof; J. W. Kebabian; R. J. Vermeulen; M. C.R. Sahadat; G. K. Montgomery; N. C. Reynolds; R. M. Warren; N. Quinn; P. Critchley; C. D. Marsden; U. K. Rinne; P. Giovannini; G. Scigliano; I. Piccolo; I. Runge; R. Horowski; P. Jeanty; M. Van Den Kerchove; A. Lowenthal; N. P. Quinn; A. E. Lang; C. Thompson; A. Wright; A. J. Lees; G. M. Stern; S. G. Diamond; C. H. Markham; L. J. Treciokas; H. D. Langtry; S. P. Clissold

doi:10.1212/wnl.45.3_suppl_3.s28

Dopamine agonists in parkinson's disease

Erik Ch. Wolters, Gerrit Tissingh, Paul L.M. Bergmans, Michael A. Kuiper, Y. Agid, P. Cervera, E. Hirsch, O. Hornykiewicz, S. J. Kish, G. E. Alexander, M. D. Crutcher, H. Bergman, T. Wichmann, M. R. Delong, G. E. Alexander, M. R. Delong, P. L. Strick, H. J. Groenewegen, H. W. Berendse, J. G. WoltersC. R. Gerfen, J. F. McGinty, W. S. Young, A. R. Crossman, B. Fornstedt, E. Pileblad, A. Carlsson, N. Ogawa, R. Edamatsu, K. Mizukawa, C. C. Chiueh, H. Miyake, M. T. Peng, S. B. Blunt, P. Jenner, C. D. Marsden, P. Jenner, D. T. Dexter, J. Sian, C. W. Olanow, I. J. Kopin, P. H. Andersen, J. A. Gingrich, M. D. Bates, R. W. Fuller, J. A. Clemens, D. L. Felten, S. Y. Felten, R. W. Fuller, J. L. Waddington, K. M. O'boyle, J. K.C. Tsui, R. F. Wolters, B. Gomez-Mancilla, R. Boucher, C. Gagnon, M. Emre, U. K. Rinne, A. Rascol, R. J. Vermeulen, B. Drukarch, M. C.R. Sahadat, J. C. Stoof, J. W. Kebabian, R. J. Vermeulen, M. C.R. Sahadat, G. K. Montgomery, N. C. Reynolds, R. M. Warren, N. Quinn, P. Critchley, C. D. Marsden, U. K. Rinne, P. Giovannini, G. Scigliano, I. Piccolo, I. Runge, R. Horowski, P. Jeanty, M. Van Den Kerchove, A. Lowenthal, N. P. Quinn, A. E. Lang, C. Thompson, A. Wright, A. J. Lees, G. M. Stern, S. G. Diamond, C. H. Markham, L. J. Treciokas, H. D. Langtry, S. P. Clissold

Research output: Contribution to journal › Article › peer-review

57 Scopus citations

Abstract

The main pathologic hallmark of Parkinson's disease is a degeneration of the dopaminergic cells in the substantia nigra, pars compacta and-to a lesser extent--in the ventral tegmental area. Striatal dopamine concentrations are significantly reduced before clinical symptoms become apparent. Recent neuroanatomic and function studies have revealed that the nigrostriatal dopaminergic projection is only one of the neuronal elements integrated into extensive basal ganglia-thalamocortical circuits that are intimately involved in the regulation of motor activity. The possibilities for therapeutic intervention at the level of the different dopamine receptor subtypes and their effect on the regulation of motor behavior will be briefly reviewed. Dopamine precursors are considered to provide the best symptomatic treatment, whereas dopamine agonists, although less effective, might be important in slowing the progression of the disease. Our results with pergolide as monotherapy and in combination therapy in patients with Parkinson's disease also are discussed.

Original language	English
Pages (from-to)	S28-S34
Journal	Neurology
Volume	45
Issue number	3
DOIs	https://doi.org/10.1212/wnl.45.3_suppl_3.s28
State	Published - Mar 1995
Externally published	Yes

Access to Document

10.1212/wnl.45.3_suppl_3.s28

Cite this

Ch. Wolters, E., Tissingh, G., Bergmans, P. L. M., Kuiper, M. A., Agid, Y., Cervera, P., Hirsch, E., Hornykiewicz, O., Kish, S. J., Alexander, G. E., Crutcher, M. D., Bergman, H., Wichmann, T., Delong, M. R., Alexander, G. E., Delong, M. R., Strick, P. L., Groenewegen, H. J., Berendse, H. W., ... Clissold, S. P. (1995). Dopamine agonists in parkinson's disease. Neurology, 45(3), S28-S34. https://doi.org/10.1212/wnl.45.3_suppl_3.s28

@article{c773a3c66668467599daa823f7fb2d0d,

title = "Dopamine agonists in parkinson's disease",

abstract = "The main pathologic hallmark of Parkinson's disease is a degeneration of the dopaminergic cells in the substantia nigra, pars compacta and-to a lesser extent--in the ventral tegmental area. Striatal dopamine concentrations are significantly reduced before clinical symptoms become apparent. Recent neuroanatomic and function studies have revealed that the nigrostriatal dopaminergic projection is only one of the neuronal elements integrated into extensive basal ganglia-thalamocortical circuits that are intimately involved in the regulation of motor activity. The possibilities for therapeutic intervention at the level of the different dopamine receptor subtypes and their effect on the regulation of motor behavior will be briefly reviewed. Dopamine precursors are considered to provide the best symptomatic treatment, whereas dopamine agonists, although less effective, might be important in slowing the progression of the disease. Our results with pergolide as monotherapy and in combination therapy in patients with Parkinson's disease also are discussed.",

author = "{Ch. Wolters}, Erik and Gerrit Tissingh and Bergmans, {Paul L.M.} and Kuiper, {Michael A.} and Y. Agid and P. Cervera and E. Hirsch and O. Hornykiewicz and Kish, {S. J.} and Alexander, {G. E.} and Crutcher, {M. D.} and H. Bergman and T. Wichmann and Delong, {M. R.} and Alexander, {G. E.} and Delong, {M. R.} and Strick, {P. L.} and Groenewegen, {H. J.} and Berendse, {H. W.} and Wolters, {J. G.} and Gerfen, {C. R.} and McGinty, {J. F.} and Young, {W. S.} and Crossman, {A. R.} and B. Fornstedt and E. Pileblad and A. Carlsson and N. Ogawa and R. Edamatsu and K. Mizukawa and Chiueh, {C. C.} and H. Miyake and Peng, {M. T.} and Blunt, {S. B.} and P. Jenner and Marsden, {C. D.} and P. Jenner and Dexter, {D. T.} and J. Sian and Olanow, {C. W.} and Kopin, {I. J.} and Andersen, {P. H.} and Gingrich, {J. A.} and Bates, {M. D.} and Fuller, {R. W.} and Clemens, {J. A.} and Felten, {D. L.} and Felten, {S. Y.} and Fuller, {R. W.} and Waddington, {J. L.} and O'boyle, {K. M.} and Tsui, {J. K.C.} and Wolters, {R. F.} and B. Gomez-Mancilla and R. Boucher and C. Gagnon and M. Emre and Rinne, {U. K.} and A. Rascol and Vermeulen, {R. J.} and B. Drukarch and Sahadat, {M. C.R.} and Stoof, {J. C.} and Kebabian, {J. W.} and Vermeulen, {R. J.} and Sahadat, {M. C.R.} and Montgomery, {G. K.} and Reynolds, {N. C.} and Warren, {R. M.} and N. Quinn and P. Critchley and Marsden, {C. D.} and Rinne, {U. K.} and P. Giovannini and G. Scigliano and I. Piccolo and I. Runge and R. Horowski and P. Jeanty and {Van Den Kerchove}, M. and A. Lowenthal and Quinn, {N. P.} and Lang, {A. E.} and C. Thompson and A. Wright and Lees, {A. J.} and Stern, {G. M.} and Diamond, {S. G.} and Markham, {C. H.} and Treciokas, {L. J.} and Langtry, {H. D.} and Clissold, {S. P.}",

year = "1995",

month = mar,

doi = "10.1212/wnl.45.3_suppl_3.s28",

language = "אנגלית",

volume = "45",

pages = "S28--S34",

journal = "Neurology",

issn = "0028-3878",

publisher = "Lippincott Williams and Wilkins Ltd.",

number = "3",

}

Ch. Wolters, E, Tissingh, G, Bergmans, PLM, Kuiper, MA, Agid, Y, Cervera, P, Hirsch, E, Hornykiewicz, O, Kish, SJ, Alexander, GE, Crutcher, MD, Bergman, H, Wichmann, T, Delong, MR, Alexander, GE, Delong, MR, Strick, PL, Groenewegen, HJ, Berendse, HW, Wolters, JG, Gerfen, CR, McGinty, JF, Young, WS, Crossman, AR, Fornstedt, B, Pileblad, E, Carlsson, A, Ogawa, N, Edamatsu, R, Mizukawa, K, Chiueh, CC, Miyake, H, Peng, MT, Blunt, SB, Jenner, P, Marsden, CD, Jenner, P, Dexter, DT, Sian, J, Olanow, CW, Kopin, IJ, Andersen, PH, Gingrich, JA, Bates, MD, Fuller, RW, Clemens, JA, Felten, DL, Felten, SY, Fuller, RW, Waddington, JL, O'boyle, KM, Tsui, JKC, Wolters, RF, Gomez-Mancilla, B, Boucher, R, Gagnon, C, Emre, M, Rinne, UK, Rascol, A, Vermeulen, RJ, Drukarch, B, Sahadat, MCR, Stoof, JC, Kebabian, JW, Vermeulen, RJ, Sahadat, MCR, Montgomery, GK, Reynolds, NC, Warren, RM, Quinn, N, Critchley, P, Marsden, CD, Rinne, UK, Giovannini, P, Scigliano, G, Piccolo, I, Runge, I, Horowski, R, Jeanty, P, Van Den Kerchove, M, Lowenthal, A, Quinn, NP, Lang, AE, Thompson, C, Wright, A, Lees, AJ, Stern, GM, Diamond, SG, Markham, CH, Treciokas, LJ, Langtry, HD & Clissold, SP 1995, 'Dopamine agonists in parkinson's disease', Neurology, vol. 45, no. 3, pp. S28-S34. https://doi.org/10.1212/wnl.45.3_suppl_3.s28

TY - JOUR

T1 - Dopamine agonists in parkinson's disease

AU - Ch. Wolters, Erik

AU - Tissingh, Gerrit

AU - Bergmans, Paul L.M.

AU - Kuiper, Michael A.

AU - Agid, Y.

AU - Cervera, P.

AU - Hirsch, E.

AU - Hornykiewicz, O.

AU - Kish, S. J.

AU - Alexander, G. E.

AU - Crutcher, M. D.

AU - Bergman, H.

AU - Wichmann, T.

AU - Delong, M. R.

AU - Alexander, G. E.

AU - Delong, M. R.

AU - Strick, P. L.

AU - Groenewegen, H. J.

AU - Berendse, H. W.

AU - Wolters, J. G.

AU - Gerfen, C. R.

AU - McGinty, J. F.

AU - Young, W. S.

AU - Crossman, A. R.

AU - Fornstedt, B.

AU - Pileblad, E.

AU - Carlsson, A.

AU - Ogawa, N.

AU - Edamatsu, R.

AU - Mizukawa, K.

AU - Chiueh, C. C.

AU - Miyake, H.

AU - Peng, M. T.

AU - Blunt, S. B.

AU - Jenner, P.

AU - Marsden, C. D.

AU - Jenner, P.

AU - Dexter, D. T.

AU - Sian, J.

AU - Olanow, C. W.

AU - Kopin, I. J.

AU - Andersen, P. H.

AU - Gingrich, J. A.

AU - Bates, M. D.

AU - Fuller, R. W.

AU - Clemens, J. A.

AU - Felten, D. L.

AU - Felten, S. Y.

AU - Fuller, R. W.

AU - Waddington, J. L.

AU - O'boyle, K. M.

AU - Tsui, J. K.C.

AU - Wolters, R. F.

AU - Gomez-Mancilla, B.

AU - Boucher, R.

AU - Gagnon, C.

AU - Emre, M.

AU - Rinne, U. K.

AU - Rascol, A.

AU - Vermeulen, R. J.

AU - Drukarch, B.

AU - Sahadat, M. C.R.

AU - Stoof, J. C.

AU - Kebabian, J. W.

AU - Vermeulen, R. J.

AU - Sahadat, M. C.R.

AU - Montgomery, G. K.

AU - Reynolds, N. C.

AU - Warren, R. M.

AU - Quinn, N.

AU - Critchley, P.

AU - Marsden, C. D.

AU - Rinne, U. K.

AU - Giovannini, P.

AU - Scigliano, G.

AU - Piccolo, I.

AU - Runge, I.

AU - Horowski, R.

AU - Jeanty, P.

AU - Van Den Kerchove, M.

AU - Lowenthal, A.

AU - Quinn, N. P.

AU - Lang, A. E.

AU - Thompson, C.

AU - Wright, A.

AU - Lees, A. J.

AU - Stern, G. M.

AU - Diamond, S. G.

AU - Markham, C. H.

AU - Treciokas, L. J.

AU - Langtry, H. D.

AU - Clissold, S. P.

PY - 1995/3

Y1 - 1995/3

N2 - The main pathologic hallmark of Parkinson's disease is a degeneration of the dopaminergic cells in the substantia nigra, pars compacta and-to a lesser extent--in the ventral tegmental area. Striatal dopamine concentrations are significantly reduced before clinical symptoms become apparent. Recent neuroanatomic and function studies have revealed that the nigrostriatal dopaminergic projection is only one of the neuronal elements integrated into extensive basal ganglia-thalamocortical circuits that are intimately involved in the regulation of motor activity. The possibilities for therapeutic intervention at the level of the different dopamine receptor subtypes and their effect on the regulation of motor behavior will be briefly reviewed. Dopamine precursors are considered to provide the best symptomatic treatment, whereas dopamine agonists, although less effective, might be important in slowing the progression of the disease. Our results with pergolide as monotherapy and in combination therapy in patients with Parkinson's disease also are discussed.

AB - The main pathologic hallmark of Parkinson's disease is a degeneration of the dopaminergic cells in the substantia nigra, pars compacta and-to a lesser extent--in the ventral tegmental area. Striatal dopamine concentrations are significantly reduced before clinical symptoms become apparent. Recent neuroanatomic and function studies have revealed that the nigrostriatal dopaminergic projection is only one of the neuronal elements integrated into extensive basal ganglia-thalamocortical circuits that are intimately involved in the regulation of motor activity. The possibilities for therapeutic intervention at the level of the different dopamine receptor subtypes and their effect on the regulation of motor behavior will be briefly reviewed. Dopamine precursors are considered to provide the best symptomatic treatment, whereas dopamine agonists, although less effective, might be important in slowing the progression of the disease. Our results with pergolide as monotherapy and in combination therapy in patients with Parkinson's disease also are discussed.

UR - http://www.scopus.com/inward/record.url?scp=0029263201&partnerID=8YFLogxK

U2 - 10.1212/wnl.45.3_suppl_3.s28

DO - 10.1212/wnl.45.3_suppl_3.s28

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 7715794

AN - SCOPUS:0029263201

SN - 0028-3878

VL - 45

SP - S28-S34

JO - Neurology

JF - Neurology

IS - 3

ER -

Dopamine agonists in parkinson's disease

Abstract

Access to Document

Other files and links

Fingerprint

Cite this